Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

In Vivo Generation of Memory-like NK Cells for the Treatment of AML and Myelodysplastic Syndrome; Early Clinical Applications of INKmune TM

Kim H. Orchard, Helena Ballestero, Aga Zubiak, Chris Dalley, Deborah Susan Richardson, Rob Torrance, Trinity Eales, Dimitra Peppa, May Sabry, Mark W. Lowdell

Blood (2022) 140 (Supplement 1): 4590–4591.

https://doi.org/10.1182/blood-2022-166175

Published: 2022

Journal Articles

Safety, Efficiency and Long-Term Follow-up of AUTO1, a Fast-Off Rate CD19 CAR in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia and Other B-Cell Malignancies

Blood (2022) 140 (Supplement 1): 7452–7453.

https://doi.org/10.1182/blood-2022-167053

Published: 2022

Journal Articles

Safety and Efficacy of AUTO1, a Fast-Off Rate CD19 CAR in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL)

Blood (2021) 138 (Supplement 1): 3823.

https://doi.org/10.1182/blood-2021-146316

Published: 2021

Journal Articles

ALLCAR19: Updated Data Using AUTO1, a Novel Fast-Off Rate CD19 CAR in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia and Other B-Cell Malignancies

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-137768

Published: 2020

Journal Articles

Automated Manufacture of Matched Donor-Derived Allogeneic CD19 CAR T-Cells for Relapsed/Refractory B-ALL Following Allogeneic Stem Cell Transplantation: Toxicity, Efficacy and the Important Role of Lymphodepletion

Blood (2019) 134 (Supplement_1): 776.

https://doi.org/10.1182/blood-2019-129640

Published: 2019

Journal Articles

AUTO1, a Novel Fast Off CD19CAR Delivers Durable Remissions and Prolonged CAR T Cell Persistence with Low CRS or Neurotoxicity in Adult ALL

Blood (2019) 134 (Supplement_1): 226.

https://doi.org/10.1182/blood-2019-131086

Published: 2019

Journal Articles

Predictors of Response in Patients Receiving CD34-Selected Stem Cell Infusions without Conditioning to Correct Graft Failure Following Allogeneic Stem Cell Transplantation

Maria del Mar Cuadrado, MBBS, Mark W. Lowdell, BSc, MSc, PhD FRCPath, Stuart Ings, Michael J. Watts, PhD, Richard Szydlo, PhD, Chloe Anthias, MD, J. Alejandro Madrigal, MDPhDDSc,FRCP,FRCPath, Panagiotis Kottaridis, FRCPath,PhDMSc, Ben Carpenter, PhD, Rachael Hough, MD BMBS, FRCP, FRCPath, Karl Peggs, MBBChir, Kirsty Thomson, PhD, Emma Morris, FRCPath, MA, MBBChir, PhD MRCP, Ronjon Chakraverty, BMBS, PhD

Blood (2018) 132 (Supplement 1): 204.

https://doi.org/10.1182/blood-2018-99-115054

Published: 2018

Journal Articles

Preliminary Results of a Phase 1/2 Clinical Trial of Cndo-109-Activated Allogeneic Natural Killer Cells in High Risk Acute Myelogenous Leukemia Patients in First Complete Remission

Todd A. Fehniger, MD PhD, Robert K Stuart, MD, Sarah A. Cooley, MD MS, Jeffrey S. Miller, MD, Julie Curtsinger, PhD, Timothy Mark Hillman, MSc, Nova Silver, RN, Michael Szarek, PhD, Mark W Lowdell, BSc, MSc, PhD FRCPath, Leonid Gorelik, PhD, Eric Rowinsky, MD

Blood (2014) 124 (21): 2320.

https://doi.org/10.1182/blood.V124.21.2320.2320

Published: 2014

Journal Articles

Results of a Phase 1 Clinical Trial of Allogeneic Tumor-Primed Natural Killer Cells in AML

Panagiotis Kottaridis, MD, PhD, Maria Tsirogianni, MD, Janet North, BSc, MSc, Chloe Marden, PhD, Stephen Mackinnon, MD, Mark W Lowdell, PhD, FRCPath

Blood (2011) 118 (21): 946.

https://doi.org/10.1182/blood.V118.21.946.946

Published: 2011

Journal Articles

The JAK3-selective inhibitor PF-956980 reverses the resistance to cytotoxic agents induced by interleukin-4 treatment of chronic lymphocytic leukemia cells: potential for reversal of cytoprotection by the microenvironment

Andrew J. Steele, Archibald G. Prentice, Kate Cwynarski, A. Victor Hoffbrand, Stephen M. Hart, Mark W. Lowdell, Edward R. Samuel, R. Gitendra Wickremasinghe

Blood (2010) 116 (22): 4569–4577.

https://doi.org/10.1182/blood-2009-09-245811

Published: 2010

Includes: Supplemental data

Journal Articles

Detection of Immunophenotypic Residual Disease After Induction Therapy Is An Independent Prognostic Factor for Duration of Remission In Older AML Patients Treated Intensively

Sylvie Freeman, Robert Hills, MA, MSc, DPhil, Paul Virgo, Steve Couzens, Mark W Lowdell, BSc, MSc, PhD, FRCPath, Christopher J McNamara, Paul White, Alan Burnett

Blood (2010) 116 (21): 2714.

https://doi.org/10.1182/blood.V116.21.2714.2714

Published: 2010

Journal Articles

CMV-Reactive T Cells Can Be Isolated From G-CSF Mobilised Peripheral Blood Apheresates.

Edward R Samuel, MSc, Katy Newton, PhD, Stephen Mackinnon, MD, Mark W Lowdell, PhD, FRCPath

Blood (2010) 116 (21): 1276.

https://doi.org/10.1182/blood.V116.21.1276.1276

Published: 2010

Journal Articles

CMV-Reactive γ/δ T Cells Are Equivalent to Their α/β Counterparts In the Lysis of CMV-Infected Targets – Potential for Post Transplant Adoptive Immunotherapy.

Andrea Knight, PhD, Stephen Mackinnon, MD, Mark W Lowdell, PhD, FRCPath

Blood (2010) 116 (21): 1277.

https://doi.org/10.1182/blood.V116.21.1277.1277

Published: 2010

Journal Articles

The role of Vδ2-negative γδ T cells during cytomegalovirus reactivation in recipients of allogeneic stem cell transplantation

Andrea Knight, Alejandro J. Madrigal, Sarah Grace, Janani Sivakumaran, Panagiotis Kottaridis, Stephen Mackinnon, Paul J. Travers, Mark W. Lowdell

Blood (2010) 116 (12): 2164–2172.

https://doi.org/10.1182/blood-2010-01-255166

Published: 2010

Journal Articles

Adoptive Transfer of CMV-Specific Donor T Cells Following Allogeneic Transplantation Leads to Rapid and Safe Systemic Reconstitution.

Karl S Peggs, MD, Kirsty Thomson, MD, Edward Samuel, BSc, MSc, Gemma Dyer, Julie Armoogum, Kwok Pang, BSc, MSc, Ronjon Chakraverty, MD, PhD, Stephen Mackinnon, MD, Mark W Lowdell, PhD, FRCPath

Blood (2009) 114 (22): 44.

https://doi.org/10.1182/blood.V114.22.44.44

Published: 2009

Journal Articles

CMV-Reactive Gamma/Delta T Cells Expanded From CMV Seronegative Normal Healthy Individuals Lyse CMV-Infected Targets – Potential Adoptive Immunotherapy for Recipients of Stem Cell Transplants From CMV Seronegative Donors.

Andrea Knight, PhD, Stephen Mackinnon, MD, Mark W Lowdell, PhD, FRCPath

Blood (2009) 114 (22): 2233.

https://doi.org/10.1182/blood.V114.22.2233.2233

Published: 2009

Journal Articles

2-phenylacetylenesulfonamide (PAS) induces p53-independent apoptotic killing of B-chronic lymphocytic leukemia (CLL) cells

Andrew J. Steele, Archibald G. Prentice, A. Victor Hoffbrand, Birunthini C. Yogashangary, Stephen M. Hart, Mark W. Lowdell, Edward R. Samuel, Janet M. North, Elisabeth P. Nacheva, Anastasios Chanalaris, Panagiotis Kottaridis, Kate Cwynarski, R. Gitendra Wickremasinghe

Blood (2009) 114 (6): 1217–1225.

https://doi.org/10.1182/blood-2008-11-190587

Published: 2009

Includes: Supplemental data

Journal Articles

A Phase I/II Clinical Trial of Tumour-Activated Allogeneic Natural Killer Cells in AML

Panos Kottaridis, Janet North, Ismail Bakhsh, Edward Samuel, Stephen Mackinnon, Mark W Lowdell, PhD, FRCPath

Blood (2008) 112 (11): 2901.

https://doi.org/10.1182/blood.V112.11.2901.2901

Published: 2008

Journal Articles

Tumor-Activated Human NK Cells Specificall Ylyse Autologous and Allogeneic NK-Resistant Tumor Targets.

Mark W. Lowdell, PhD, Ismail Bakhsh, MSc, Janet North, MSc, Chloe Marden, PhD, Elena Addison, MSc, Stephen Mackinnon, MD

Blood (2006) 108 (11): 3707.

https://doi.org/10.1182/blood.V108.11.3707.3707

Published: 2006

Journal Articles

Direct Isolation of Donor-Derived Antigen - Specific T Cells and Their Adoptive Transfer for Treatment or Prophylaxis of CMV Infection Following Allogeneic Transplantation.

Kirsty Thomson, MD, Moran Julie, BSc, Kwok Pang, MSc, Ed Samuel, BSc, Michael Desborough, BSc, Mark W. Lowdell, PhD, Stephen Mackinnon, MD

Blood (2006) 108 (11): 589.

https://doi.org/10.1182/blood.V108.11.589.589

Published: 2006

NARROW

In Vivo Generation of Memory-like NK Cells for the Treatment of AML and Myelodysplastic Syndrome; Early Clinical Applications of INKmune TM

Safety, Efficiency and Long-Term Follow-up of AUTO1, a Fast-Off Rate CD19 CAR in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia and Other B-Cell Malignancies

Safety and Efficacy of AUTO1, a Fast-Off Rate CD19 CAR in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL)

ALLCAR19: Updated Data Using AUTO1, a Novel Fast-Off Rate CD19 CAR in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia and Other B-Cell Malignancies

Automated Manufacture of Matched Donor-Derived Allogeneic CD19 CAR T-Cells for Relapsed/Refractory B-ALL Following Allogeneic Stem Cell Transplantation: Toxicity, Efficacy and the Important Role of Lymphodepletion

AUTO1, a Novel Fast Off CD19CAR Delivers Durable Remissions and Prolonged CAR T Cell Persistence with Low CRS or Neurotoxicity in Adult ALL

Predictors of Response in Patients Receiving CD34-Selected Stem Cell Infusions without Conditioning to Correct Graft Failure Following Allogeneic Stem Cell Transplantation

Preliminary Results of a Phase 1/2 Clinical Trial of Cndo-109-Activated Allogeneic Natural Killer Cells in High Risk Acute Myelogenous Leukemia Patients in First Complete Remission

Results of a Phase 1 Clinical Trial of Allogeneic Tumor-Primed Natural Killer Cells in AML

The JAK3-selective inhibitor PF-956980 reverses the resistance to cytotoxic agents induced by interleukin-4 treatment of chronic lymphocytic leukemia cells: potential for reversal of cytoprotection by the microenvironment

Detection of Immunophenotypic Residual Disease After Induction Therapy Is An Independent Prognostic Factor for Duration of Remission In Older AML Patients Treated Intensively

CMV-Reactive T Cells Can Be Isolated From G-CSF Mobilised Peripheral Blood Apheresates.

CMV-Reactive γ/δ T Cells Are Equivalent to Their α/β Counterparts In the Lysis of CMV-Infected Targets – Potential for Post Transplant Adoptive Immunotherapy.

The role of Vδ2-negative γδ T cells during cytomegalovirus reactivation in recipients of allogeneic stem cell transplantation

Adoptive Transfer of CMV-Specific Donor T Cells Following Allogeneic Transplantation Leads to Rapid and Safe Systemic Reconstitution.

CMV-Reactive Gamma/Delta T Cells Expanded From CMV Seronegative Normal Healthy Individuals Lyse CMV-Infected Targets – Potential Adoptive Immunotherapy for Recipients of Stem Cell Transplants From CMV Seronegative Donors.

2-phenylacetylenesulfonamide (PAS) induces p53-independent apoptotic killing of B-chronic lymphocytic leukemia (CLL) cells

A Phase I/II Clinical Trial of Tumour-Activated Allogeneic Natural Killer Cells in AML

Tumor-Activated Human NK Cells Specificall Ylyse Autologous and Allogeneic NK-Resistant Tumor Targets.

Direct Isolation of Donor-Derived Antigen - Specific T Cells and Their Adoptive Transfer for Treatment or Prophylaxis of CMV Infection Following Allogeneic Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only